Leo Kim is an Ophthalmology physician affiliated with Massachusetts Eye and Ear Infirmary. OpenAlex indexes 264 publications with 6,370 citations (h-index 40); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
243 Charles St
Retina Service
Boston, MA 021143002
Telephone
617-391-5896Registry record last updated 18 Dec 2013.
Clinical trials
- The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
Sponsor: Massachusetts Eye and Ear Infirmary
- Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
Sponsor: Massachusetts Eye and Ear Infirmary
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year20253 payments
- Stryker CorporationProgram year20252 payments
- Ocular Therapeutix, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
65.7%Corticosteroid41.4%Prednisolone Acetate100%Part D≥16 patientsCarbonic Anhydrase Inhibitor24.3%Dorzolamide-Timolol100%Part D<11 patientsMusculoskeletal
34.3%Cyclooxygenase Inhibitor34.3%Ketorolac Tromethamine100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2016–2022 per NIH RePORTER. The latest:
- Role of Runx1 in Pathologic Ocular Angiogenesis
Schepens Eye Research Institute
FY2022$502,164R01EY027739 - Role of Runx1 in Pathologic Ocular Angiogenesis
Schepens Eye Research Institute
FY2021$528,075R01EY027739 - Role of Runx1 in Pathologic Ocular Angiogenesis
Schepens Eye Research Institute
FY2020$544,408R01EY027739
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
John Kempen, MD
Massachusetts Eye and Ear Infirmary
Neil Bhattacharyya, MD, FACS
Massachusetts Eye and Ear Infirmary
Demetrios Vavvas, MD, PhD
Massachusetts Eye and Ear Infirmary
Evangelos Gragoudas, MD
Massachusetts Eye and Ear Infirmary
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”